Funding profile · AI drug discovery

1910 Genetics

One Form D on file, from 2021, and one undisclosed strategic investment from Accenture Ventures three years later. Here is what the single SEC filing shows, and what is still missing from the public record.

$25.7MTotal sold, sole Form D on file (filed Apr 2021)
$26.1MCombined seed and Series A, company-reported (2024 releases)
19Investors named on the 2021 Form D, about $1.35M each on average
$546KFederal grant on record (NIH STTR, 2021 to 2023)

Data as of September 24, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Before 2021 Seed, previously unannounced $4.1M Led by Sam Altman; FoundersX Ventures, Y Combinator, Scientia Ventures, Emles Advisors, Tuck Lye Koh of Shunwei Capital and others Independent
First sale Jan 29, 2021 Series A $22M announced; $25.7M total sold per the combined Form D Co-led by M12 (Microsoft’s Venture Fund) and Playground Global; Samir Kumar and Jory Bell joined the board Form D + release
Jul 2021 to Dec 2023 NIH STTR Phase I $546,376 NINDS, project 1R41NS118992-01 NIH
Oct 31, 2024 Strategic investment Not disclosed Accenture, through Accenture Ventures Company release

What the filings show

1910 Genetics Inc. · Form D · filed Apr 19, 2021

First sale
Jan 29, 2021
Offered
$25,709,907 equity
Sold
$25,709,907 · $0 remaining
Investors
19 · average about $1,353,000
Exemption
Rule 506(b)
Related persons
Jennifer O. Nwankwo (executive officer, director); Samir Kumar (director, M12); Jory Bell (director, Playground Global); Marc Foster (director)
Filing
SEC EDGAR, CIK 0001855990

Reading the filings

  1. The filing folds two announced rounds into one number.Company materials describe an unannounced $4.1 million seed led by Sam Altman, followed by a $22 million Series A co-led by M12 and Playground Global, both closing by March 2021. The Form D covers both as a single offering with a first sale date of January 29, 2021 and shows $25,709,907 sold, close to but not identical to either the $4.1M plus $22M sum ($26.1M) the company gives in 2024 press materials. The roughly $400,000 gap is not explained in the filing; it could reflect rounding, a slightly lower final close, or proceeds counted differently between the SEC filing and the company’s own later figure.
  2. Nineteen checks, institutional size.$25.7 million split across 19 investors averages about $1.35 million each. That is consistent with the venture funds named in the announcement (M12, Playground Global) rather than a large syndicate of small angels, even though Sam Altman and other named angels also participated.
  3. Only one Form D exists.No filing appears for 1910 Genetics before or after April 2021, including nothing tied to the October 2024 Accenture Ventures investment. Companies can raise money under exemptions that do not require a Form D, or Accenture’s stake could have come through a different instrument (a note, a side letter, or a purchase of existing shares) that would not generate a new Regulation D notice. The public record simply does not size that later investment.
  4. The board on file is small and investor-heavy.The 2021 filing lists founder and CEO Jennifer Nwankwo alongside three outside directors: Samir Kumar of M12, Jory Bell of Playground Global, and Marc Foster. No later filing updates this list.
  5. Non-dilutive money is a small, separate slice.The $546,376 NIH STTR award for a chronic-pain program is not part of the equity round and is the only NIH or NSF funding found under the company’s name.

Commercial signals

Signal Detail Source type
Technology partnership Five-year commercial agreement with Microsoft, announced Feb 2024, on Azure Quantum Elements, following a private preview from Jun 2023. Confirmed both sides
Strategic investor Accenture Ventures invested and agreed to a business collaboration, Oct 2024. Terms not disclosed by either party. Company and partner stated
Named biopharma customers None found publicly. Partners named to date, Microsoft and Accenture, are a cloud and technology company and a professional services firm, not biopharma companies buying a drug-discovery program. Not found
Internal pipeline evidence One pending patent application, US20250257051A1, naming a TYK2 inhibitor program, priority date Jul 2022, published Aug 2025. Public record
Clinical stage No registered clinical trial and no FDA filing found, consistent with a preclinical-stage discovery platform. Not found

What to watch

  • A new Form D or other public filing that sizes the Accenture Ventures investment.
  • Any amendment to the 2021 Form D reconciling the $25.7M filed figure with the $26.1M the company now cites.
  • A named biopharma partner paying for a co-discovery or co-engineering program under the Microsoft deal.
  • Movement on the TYK2 program named in the 2025 patent application, including any new grant, publication or trial filing.

The 1910 Genetics story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • LunaJoy Health: Shared investor: Foundersx Ventures. A telehealth company built by two physicians to close the gap between a positive mental health screening and actual treatment for women
  • HelpNow: Shared investor: Emles Venture Partners. An app that aggregates private ambulances and converts rideshare cabs into medical first responder vehicles in India
  • Exin Therapeutics: Also in Therapeutics. Three Oxford neuroscientists building circuit level gene therapies for epilepsy, guided by AI models trained on mouse brain recordings
  • Origami Therapeutics: Also in Therapeutics. A small San Diego company designing oral pills that strip the mutant huntingtin protein out of brain cells while leaving the normal protein alone

Sources

  1. Public recordForm D, 1910 Genetics Inc.SEC EDGAR, CIK 0001855990 · filed Apr 19, 2021
  2. Public recordNIH RePORTER, award 1R41NS118992-01NINDS · FY2021
  3. Public recordSBIR.gov award record, 1910 Genetics Inc.SBIR.gov
  4. Public recordUS20250257051A1, Substituted pyrimidine compounds as tyk2 inhibitorsUSPTO, published via Google Patents · published Aug 14, 2025
  5. Independent1910 Genetics Raises $26M in Seed and Series A FundingFinSMEs · Mar 25, 2021
  6. Independent1910 Genetics launches to accelerate therapeutics designDrug Discovery World, Megan Thomas · Mar 26, 2021
  7. IndependentMicrosoft, 1910 Genetics eye biopharma breakthroughsDrug Discovery and Development, Brian Buntz · Feb 29, 2024
  8. InvestorWelcoming 1910 Genetics to the M12 PortfolioM12, Microsoft’s Venture Fund · Mar 23, 2021
  9. CompanyMicrosoft and 1910 Genetics Partner to Build the Infrastructure Layer for Drug Discovery and Development Using AI and High-Performance ComputingBusiness Wire · Feb 29, 2024
  10. CompanyAccenture Collaborates with 1910 Genetics to Help Biopharma Companies Transform Drug Discovery with AIAccenture Newsroom · Oct 31, 2024

Compiled from SEC, NIH and USPTO public records and published reports as of September 24, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later, unregistered financings. Healthcare Venture Capital Fund holds no position in 1910 Genetics. This page is not an offer to sell or a recommendation to buy any security.